In a study published in JAMA Network, patients with type 2 diabetes taking GLP-1 treatments have a reduced risk of developing ten types of obesity-related cancers compared to those on insulin and other diabetes medications. GLP-1 treatments, including Novo Nordisk’s (NYSE:NVO) semaglutide (Wegvoy and Ozempic) and Eli Lilly And Co’s (NYSE:LLY) tirzepatide (Mounjaro and Zepbound), have gained tremendous popularity. The research examined the medical records of 1.6 million diabetes patients with no prior history of thirteen types of obesity-related cancers, including esophageal, colorectal, endometrial, gallbladder, kidney, liver, ...